.svg){kind=small}
Jul-2025
Sales
Trend
6-Month
Product Count
SKUs
Overview
Market Insights Snapshot
In the state of Ohio, Farmaceutical Rx (Frx) has shown varying performance across different cannabis categories. In the Edible category, the brand experienced a notable climb in rankings from April to June 2025, moving from 35th to 23rd, before dropping back to 35th in July. This fluctuation is indicative of a competitive market landscape, where maintaining a top position requires consistent strategic efforts. Meanwhile, in the Flower category, Frx demonstrated a more stable ascent, improving its rank from 32nd in April to 22nd in June, before slightly declining to 28th in July. This suggests that while the brand is gaining traction in the Flower category, it faces challenges in maintaining momentum.
The sales data further highlights Farmaceutical Rx's performance nuances. For instance, despite the drop in rank in the Edible category in July, the brand had a significant sales peak in June, suggesting that specific factors or promotions may have temporarily boosted sales. The Flower category, on the other hand, experienced a steady increase in sales from April to June, aligning with its improved ranking during this period. However, the decline in both sales and rank in July suggests potential market saturation or increased competition. These dynamics underscore the importance for Farmaceutical Rx to continuously innovate and adapt to the evolving market conditions to sustain growth and improve its standings.
Competitive Landscape
In the competitive landscape of the Ohio flower category, Farmaceutical Rx (Frx) has experienced notable fluctuations in its ranking, reflecting a dynamic market environment. From April to July 2025, Farmaceutical Rx (Frx) improved its rank from 32nd to 22nd by June, before dropping to 28th in July. This suggests a temporary surge in sales performance, potentially driven by strategic marketing or product launches, followed by a decline that may indicate increased competition or market saturation. Notably, Modern Flower saw a significant rise from 47th to 27th place by July, indicating a strong upward trend that could pose a challenge to Farmaceutical Rx (Frx) if sustained. Meanwhile, Galenas and The Standard maintained relatively stable positions, with Galenas experiencing a slight decline and The Standard showing resilience with a minor dip in July. As Farmaceutical Rx (Frx) navigates this competitive field, understanding these shifts and the strategies behind them could be crucial for maintaining and improving its market position.
Notable Products
In July 2025, Animal Face (2.83g) emerged as the top-performing product for Farmaceutical Rx (Frx), achieving the number one rank with sales of 2014 units. Banana Kush (2.83g) followed closely in the rankings, moving up to second place from its absence in June, with a notable improvement from its fifth position in May. Red Berries (2.83g) made its debut in the rankings at third place, indicating strong initial sales. Similarly, Crippy (2.83g) and Black Garlic (2.83g) entered the rankings at fourth and fifth positions, respectively, showcasing their growing popularity. The consistent rise of Animal Face (2.83g) from fourth in May to second in June, and finally to the top spot, highlights its increasing consumer demand.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
